3-{4-[(6-chloro-2-methyl-1-benzothiophen-4-yl)methoxy]-3,5-difluorophenyl}propan-1-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 3-{4-[(6-chloro-2-methyl-1-benzothiophen-4-yl)methoxy]-3,5-difluorophenyl}propan-1-ol
• 英文别名: 3-[4-[(6-Chloro-2-methyl-1-benzothiophen-4-yl)methoxy]-3,5-difluorophenyl]propan-1-ol；3-[4-[(6-chloro-2-methyl-1-benzothiophen-4-yl)methoxy]-3,5-difluorophenyl]propan-1-ol
• 化学式: C₁₉H₁₇ClF₂O₂S
• 分子量: 382.859
• InChiKey: UNOHEIIHTCXZRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  57.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Benzo-fused heterocyclic derivatives useful as agonists of GPR120
  申请人：Janssen Pharmaceutica NV

  公开号：US10155737B2

  公开（公告）日：2018-12-18

  The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

  本发明涉及苯并融合杂环衍生物、含有它们的药物组合物以及它们在治疗受 GPR120 调节的疾病和病症中的用途。更具体地说，本发明的化合物是 GPR120 的激动剂，可用于治疗例如 II 型糖尿病。
• BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120
  申请人：Janssen Pharmaceutica NV

  公开号：EP2970157B1

  公开（公告）日：2018-04-25
• US20140275172A1
  申请人：——

  公开号：US20140275172A1

  公开（公告）日：2014-09-18
• US9562053B2
  申请人：——

  公开号：US9562053B2

  公开（公告）日：2017-02-07
• [EN] BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES À CONDENSATION BENZO UTILES EN TANT QU'AGONISTES DE GPR120
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2014159061A2

  公开（公告）日：2014-10-02

  The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.